

Keith C Bible

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8637515/keith-c-bible-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

9,096
citations

25
h-index

55
g-index

55
ext. papers

11,383
ext. citations

6.2
avg, IF

5.72
L-index

#	Paper	IF	Citations
52	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016 , 26, 1-133	6.2	6910
51	American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid</i> , 2012 , 22, 1104-39	6.2	524
50	Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. <i>Lancet Oncology, The</i> , 2010 , 11, 962-72	21.7	326
49	A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3179-84	5.6	124
48	Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. <i>Thyroid</i> , 2011 , 21, 25-30	6.2	116
47	A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 1687-93	5.6	85
46	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. <i>Lancet Diabetes and Endocrinology, the</i> , 2014 , 2, 830-42	18.1	73
45	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2021 , 31, 337-386	6.2	66
44	Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. <i>Clinical Cancer Research</i> , 2005 , 11, 5935-41	12.9	61
43	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019 , 29, 7-26	6.2	59
42	Evolving molecularly targeted therapies for advanced-stage thyroid cancers. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 403-16	19.4	58
41	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4506-4514	5.6	56
40	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1943-1950	5.6	54
39	Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 138-48	6.1	54
38	Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. <i>Science Translational Medicine</i> , 2013 , 5, 166ra3	17.5	48
37	A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. <i>Gynecologic Oncology</i> , 2012 , 127, 55-62	4.9	43
36	Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 469-481	18.1	39

35	Diagnosis and Management of Anaplastic Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019 , 48, 269-284	5.5	37
34	Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2017 , 57, 220-225	4	33
33	A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2019 , 29, 1615-1622	6.2	32
32	Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1856-1864	2.2	31
31	External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. <i>Advances in Radiation Oncology</i> , 2018 , 3, 25-29	3.3	29
30	Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1357-75	5.9	29
29	Bone metastases in thyroid cancer. <i>Journal of Bone Oncology</i> , 2020 , 21, 100282	4.5	26
28	Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1546-1550	3.1	25
27	Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2017 , 27, 923-927	6.2	23
26	New drugs for medullary thyroid cancer: new promises?. <i>Endocrine-Related Cancer</i> , 2016 , 23, R287-97	5.7	16
25	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2359-2366	2.2	16
24	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma 2020 , 8,		14
23	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4387-95	5.6	11
22	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. <i>Thyroid</i> , 2020 , 30, 1254-1262	6.2	10
21	Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E936-43	5.6	9
20	Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. <i>Journal of Oncology Practice</i> , 2012 , 8, e1s-5s	3.1	9
19	Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions. <i>International Journal of Endocrine Oncology</i> , 2014 , 1, 145-151	0.3	7
18	Treating advanced radioresistant differentiated thyroid cancer. <i>Lancet Oncology</i> , 2012 , 13, 854-5	21.7	7

17	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020 , 4, bvaa069	0.4	6
16	Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma. <i>International Journal of Endocrine Oncology</i> , 2016 , 3, 285-289	0.3	5
15	Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	4
14	Mutated BRAF and personalised medicine in differentiated thyroid cancer. <i>Lancet Oncology</i> , 2016 , 17, 1181-3	21.7	4
13	Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. <i>Thyroid</i> , 2021 , 31, 332-333	6.2	3
12	Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer. <i>Endocrine</i> , 2018 , 59, 228-229	4	3
11	Toward improved outcomes in patients with anaplastic thyroid cancer. <i>Oncology</i> , 2012 , 26, 398, 401, 406	1.8	3
10	Systemic therapeutic approaches to advanced thyroid cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 389-92	7.1	2
9	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.. <i>Head and Neck</i> , 2022 ,	4.2	2
8	"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy. <i>Endocrine</i> , 2017 , 57, 187-188	4	1
7	Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned. <i>AACE Clinical Case Reports</i> , 2021 , 7, 334-335	0.7	1
6	Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas.. <i>Journal of the Endocrine Society</i> , 2022 , 6, bvac044	0.4	0
5	Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, 521-2	3.1	
4	The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.. <i>Blood</i> , 2004 , 104, 3461-3461	2.2	
3	Anaplastic Thyroid Carcinoma 2019 , 693-700		
2	Anaplastic Thyroid Cancer and Primary Thyroid Lymphoma 2021 , 246-254.e3		
1	Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. <i>American Journal of Managed Care</i> , 2012 , 18, e162-7	2.1	